Business Context and Reporting Period
This Form 8-K Current Report was filed by Cormedix Inc. on December 5, 2012. The filing addresses Item 5.02 regarding the approval of stock option awards for directors, officers, and certain employees by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on equity compensation arrangements.
Material Changes and Equity Grants
On December 5, 2012, the Compensation Committee approved option awards under the Company's 2006 Stock Incentive Plan to recognize contributions in regulatory, clinical, manufacturing, IP, and sales strategies. The total grants included:
- 25,000 shares granted to a consultant/employee.
- 765,000 shares granted to directors and executive officers.
Specific grants to named individuals were as follows:
| Name | Position | Options Granted |
|---|---|---|
| Richard M. Cohen | Executive Chairman, Interim CEO, Interim CFO, Director | 70,000 |
| Randy Milby | Chief Operating Officer | 100,000 |
| Gary Gelbfish, M.D. | Director | 70,000 |
| Matthew P. Duffy | Director | 125,000 |
| Steven Lefkowitz | Director | 150,000 |
| Anthony E. Pfaffle, M.D. | Director | 250,000 |
Terms, Vesting, and Outlook
Exercise Price: $0.68 per share, based on the closing sale price on the NYSE-MKT on December 5, 2012.
Vesting Schedule:
- 50% vests upon issuance of the CE Mark approval in Europe for the Neutrolin product candidate, provided approval is obtained on or before March 31, 2013.
- 50% vests on December 31, 2013.
Management Commentary: The grants were made in recognition of contributions to regulatory and clinical affairs, manufacturing, IP, and sales/distribution strategies. The filing does not contain forward-looking financial guidance or specific risk factors beyond the conditional vesting tied to regulatory approval.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2006 Stock Incentive Plan to assess remaining capacity for future grants.
- Monitor the status of the CE Mark approval for the Neutrolin product candidate, as 50% of the grants are contingent on approval by March 31, 2013.
- Review the Company's most recent 10-K or 10-Q for financial context, as this 8-K contains no financial performance data.
- Confirm the current stock price relative to the $0.68 exercise price to evaluate the intrinsic value of the grants.